Organ motion and early tumor response measurement during chemoradiotherapy for esophageal cancer.
- Conditions
- esophageal cancer10017991
- Registration Number
- NL-OMON44849
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 50
• Histologic evidence of invasive adenocarcinoma or squamous cell cancer of the esophagus
• Patient eligible for trimodality treatment (chemoradiotherapy and surgery) or definitive chemoradiotherapy
• T3N0M0 or T1-4N1-3M0. Patients with M1 disease solely on the basis of supraclavicular metastasis and not a junction tumor as primary are eligible. (AJCC 7th edition)
• WHO performance status <= 2
• Clinically operable for R0 resection in the opinion of an experienced upper gastrointestinal or thoracic surgeon for patients planned for trimodality
• Tumor localization at least 2cm from the upper esophageal sphincter and invading no more than 5cm into gastric cardia
• • Age >= 18 years
• Written informed consent before endoscopy or EUS
• Prior treatment with thoracic surgery or thoracic radiotherapy
• Pregnancy
• Severe cardiopulmonary restriction
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method